Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.97EUR
19 Oct 2018
Change (% chg)

€0.05 (+1.71%)
Prev Close
€2.92
Open
€2.93
Day's High
€3.01
Day's Low
€2.93
Volume
82,918
Avg. Vol
50,612
52-wk High
€3.60
52-wk Low
€2.40

Latest Key Developments (Source: Significant Developments)

Transgene Sells Greater China Rights Of TG6002 And TG1050 To Tasly Biopharmaceuticals
Monday, 20 Aug 2018 

Aug 20 (Reuters) - TRANSGENE SA ::COMPLETES THE SALE OF GREATER CHINA RIGHTS OF TG6002 AND TG1050 TO TASLY BIOPHARMACEUTICALS FOR $48 MILLION IN NEWLY-ISSUED SHARES.T601 AND T101 ARE NOW BEING DEVELOPED BY TASLY BIOPHARMACEUTICALS FOR PATIENTS IN GREATER CHINA.27.4 MILLION NEWLY-ISSUED SHARES OF TASLY BIOPHARMACEUTICALS HAVE BEEN DELIVERED TO TRANSGENE.TRANSGENE NOW HOLDS APPROXIMATELY 2.53% OF OUTSTANDING CAPITAL OF TASLY BIOPHARMACEUTICALS.  Full Article

Transgene Collaborates with BioInvent To Treat Solid Tumors
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - TRANSGENE SA ::BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS.‍COLLABORATION'S RESEARCH AND DEVELOPMENT COSTS, AS WELL AS REVENUES AND ROYALTIES, WILL BE SHARED 50:50​.WILL CONTRIBUTE BOTH ITS OV DESIGN AND ENGINEERING EXPERTISE AS WELL AS ITS PROPRIETARY ENGINEERED VACCINIA VIRUS.  Full Article

Transgene successfully raises 14.4 million euros
Friday, 10 Nov 2017 

Nov 10 (Reuters) - TRANSGENE SA ::TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS.‍TRANSACTION WAS OVERSUBSCRIBED, AT EUR 2.55 PER SHARE​.‍NEW SHARES WILL HAVE A PAR VALUE OF ONE EURO EACH​.‍NEW SHARES CARRY DIVIDEND RIGHTS AS FROM THEIR ISSUE DATE​.‍NEW SHARES' ADMISSION TO TRADING EXPECTED TO OCCUR ON NOV 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene launches capital increase by accelerated book-build offering
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - TRANSGENE SA ::TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING.‍CAPITAL INCREASE WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS THROUGH ISSUANCE OF UP TO 5,643,199 ORDINARY SHARES​.‍TO ISSUE OF UP TO 5,643,199 ORDINARY SHARES OF COMPANY, REPRESENTING APPROXIMATELY 10% OF EXISTING ISSUED SHARE CAPITAL​.‍GROSS PROCEEDS FROM TRANSACTION ARE EXPECTED TO BE APPROXIMATELY EUR 14 MILLION​.‍FUNDS RAISED WILL BE USED TO PURSUE CLINICAL AND PRECLINICAL DEVELOPMENT OF TRANSGENE'S INNOVATIVE IMMUNOTHERAPIES​.‍ADMISSION TO TRADING OF NEW SHARES EXPECTED TO OCCUR ON NOVEMBER 14, 2017 ON EURONEXT IN PARIS​.  Full Article

Transgene Q3 operating revenue drops to 1.4‍​ million euros
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - TRANSGENE SA ::Q3 OPERATING REVENUE EUR 1.4‍​ MILLION VERSUS EUR 1.5 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AT SEPT. 30 EUR 40.0‍​ MILLION VERSUS EUR 56.2 MILLION AT DEC. 31, 2016.CONFIRMS OUTLOOK OF CASH BURN ABOUT 30 MILLION EUROS‍​ IN FY 2017.  Full Article

French and Benelux stocks-Factors to watch on August 21

Aug 21 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.